Finance

Lists
EVGN:NASDAQ
Evogene Ltd
$0.54
-1.30%
(-0.0071) 1D
Sep 4, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EVGN...
Open
$0.54
High
$0.55
Low
$0.52
Mkt. cap
8.42M
Avg. vol.
462.52K
Volume
62.83K
52-wk high
$1.50
52-wk low
$0.37
EPS
-$0.91
Beta
1.40
Shares outstanding
15.80M
No. of employees
38
Open
$0.54
High
$0.55
Low
$0.52
Mkt. cap
8.42M
Avg. vol.
462.52K
Volume
62.83K
52-wk high
$1.50
52-wk low
$0.37
EPS
-$0.91
Beta
1.40
Shares outstanding
15.80M
No. of employees
38
Profile
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs. In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
About Evogene Ltd
CEOOfer Haviv
Employees38
Founded1999
Headquarters-
SectorBiotechnology
Analyst
Recommendation
Action
Price target
Projected
Date
Scott Henry
Alliance Global Partners
Buy
Maintained
$2.15
+299.7%
05/26/2026
Unknown Analyst
Alliance Global Partners
Buy
Maintained
$1.75
+225.3%
03/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
312.00K
314.00K
334.00K
347.00K
Cost of goods sold
157.00K
2.28M
130.00K
206.00K
Cost of revenue
157.00K
2.28M
130.00K
206.00K
Research and development expenses
1.38M
1.83M
1.84M
1.37M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.50M
1.20M
1.54M
1.21M
Operating expense
2.88M
3.00M
3.38M
2.70M
Total operating expenses
3.04M
5.28M
3.51M
2.91M
Operating income
-2.72M
-4.97M
-3.18M
-2.56M
Other non operating income
-
668.00K
-
-
EBT including unusual items
-2.73M
-5.34M
-5.91M
-1.59M
EBT excluding unusual items
-2.73M
-5.09M
-5.94M
-1.59M
Income tax expense
1.00K
-
4.00K
-
Effective tax rate
-0.04%
-
-0.07%
-
Other operating expenses
9.00K
-27.00K
-
122.00K
Net income
3.87M
-5.31M
-5.87M
-1.77M
Net profit margin
1,241.67%
-1,690.76%
-1,757.48%
-509.51%
Earnings per share
-0.46
-0.62
-0.61
-0.13
Interest and investment income
465.00K
1.38M
1.17M
1.14M
Interest expense
-453.00K
-1.93M
-3.88M
-168.00K
Net interest expenses
12.00K
-545.00K
-2.71M
972.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.44M
-4.70M
-2.98M
-2.41M
Gain or loss from assets sale
12.00K
-27.00K
-23.00K
9.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google apps